What's Happening?
Invivoscribe has introduced the PrepQuant™ sample preparation platform, an automated system designed to streamline and standardize pre-analytical workflows in molecular testing. Developed in collaboration with Hitachi High-Tech Corporation, the platform integrates
nucleic acid extraction, concentration, and quantification into a single instrument. This innovation aims to reduce costs and eliminate inconsistencies in molecular testing by consolidating multiple steps into one process. The system is assay agnostic, capable of generating highly concentrated genomic DNA and cell-free DNA for next-generation sequencing, qPCR, and digital PCR assays. The PrepQuant system is expected to improve operational efficiency by reducing sample variability and lab bench space requirements.
Why It's Important?
The launch of the PrepQuant system represents a significant advancement in molecular testing, particularly in the field of precision medicine. By standardizing the pre-analytical workflow, the system enhances the reliability of test results, which is crucial for applications such as measurable residual disease and liquid biopsy testing. The ability to produce consistent and high-quality starting material is vital for accurate diagnostics and treatment planning. This development could lead to more efficient laboratory operations, reduced labor costs, and minimized risk of errors, ultimately benefiting healthcare providers and patients by improving the accuracy and speed of diagnostic processes.
What's Next?
Invivoscribe plans to officially unveil the PrepQuant system at the American Association for Cancer Research (AACR) Annual Meeting in San Diego. The company is also working on expanding the system's capabilities to accommodate additional specimen types beyond blood, plasma, and bone marrow. As the system gains traction in the market, it may prompt other companies to develop similar integrated solutions, further advancing the field of molecular diagnostics. The success of the PrepQuant system could lead to broader adoption in clinical laboratories, enhancing the overall quality and efficiency of molecular testing worldwide.
